Press Release Summary:
Non-contact, stand-alone Visante(TM) OCT images anterior segment of eye, including cornea, iris, angle, and lens. Without need for ocular anesthesia or water bath, system can accurately measure corneal thickness to help qualify patients for vision correction surgery. It can also image, measure, and document both corneal flap thickness and residual stromal thickness immediately following procedure. Visante OCT aids postoperative evaluation by imaging and measuring IOLs and implants.
Original Press Release:
Carl Zeiss Meditec Launches Unique Optical Coherence Tomography System for the Anterior Segment
Visante(TM) OCT Is a Versatile, Non-Contact System for Anterior Segment Imaging and Biometry
CHICAGO, Oct. 6 / -- Carl Zeiss Meditec, Inc., a leader in ophthalmic devices and systems, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for Visante(TM) OCT. The device is the first stand-alone, high-resolution optical coherence tomography (OCT) imaging system for the anterior segment of the eye, including the cornea, iris, angle and the lens. Visante OCT is being showcased at the American Academy of Ophthalmology Annual Meeting in Chicago (Booth #3534), October 15-18.
"Our Stratus(TM) OCT is the emerging gold standard for obtaining high-resolution cross-sectional images of the retina," said Jim Taylor, Carl Zeiss Meditec president and chief executive officer. "Now with Visante OCT, this technology is customized for anterior segment applications."
Without the need for ocular anesthesia or water bath, Visante OCT can accurately measure corneal thickness to help qualify patients for vision correction surgery. In addition to providing a full-thickness pachymetry map prior to laser surgery, it is the first device to image, measure and document both corneal flap thickness and residual stromal thickness immediately following the procedure -- a crucial element in ensuring optimal surgical outcomes.
"Visante OCT provides me with the clinical confidence I demand for precise evaluation of the anterior segment," said Dr. John A. Vukich, an ophthalmologist at Davis Duehr Dean in Madison, Wis. "This technology adds a new level of accuracy and safety for patients who are considering or have already undergone LASIK surgery."
The Visante OCT software allows for precise evaluation, measurement and analysis of the anterior segment. Practical tools enable detailed planning and measurement of anterior segment structures, including anterior chamber depth (ACD), anterior chamber angles and the angle-to-angle distance (anterior chamber diameter). Visante OCT also aids postoperative evaluation by allowing imaging and measurement of intraocular lenses (IOLs) and implants in the eye.
For additional information about Visante OCT and all Carl Zeiss Meditec products, contact Customer Service at (800) 342-9821 or visit the Zeiss AAO portal at http://www.zeiss.com/aao.
About Carl Zeiss Meditec
Built on an unparalleled 150-year heritage of optical innovation, Carl Zeiss Meditec (International Securities Identification Number DE000531370) is one of the world's leading eye care solutions providers. Its product line includes systems for the diagnosis and treatment of the four main diseases of the eye: refraction, cataract, glaucoma and retinal disorders.
The company has incorporated its technologically superior optics into a stream of product innovations throughout the years, from slit lamps and fundus cameras; to the Humphrey(R) Field Analyzer, recognized as the global standard for glaucoma detection and management; to its newest applications of lasers and light as embodied in its leading-edge MEL-80(TM) refractive laser and eye-scanning Stratus OCT(TM) optical coherence tomographer.
Carl Zeiss Meditec AG is based in Jena, Germany, with key subsidiaries in the U.S. (Carl Zeiss Meditec Inc.) and Japan (Carl Zeiss Meditec Limited). The rapidly aging global population and other trends are expected to grow the ophthalmic market through 2010, and the company is focused on applying innovative optical technologies to protect and enhance vision now and into the future.